BioSight
Companies
OCULAR THERAPEUTIX, INC logo

OCUL

NASDAQBEDFORD, MA
OCULAR THERAPEUTIX, INC

Ocular Therapeutix develops injectable and implantable eye medications using a proprietary bioresorbable hydrogel technology called ELUTYX. The pipeline includes AXPAXLI, an injected treatment in Phase 3 trials for wet age-related macular degeneration and diabetic retinopathy; OTX-TIC, a glaucoma candidate in development; and DEXTENZA, an approved product currently being commercialized. The company operates across marketed, late-stage clinical, and earlier-stage development programs targeting diseases of the back and front of the eye.

Price history not yet available for OCUL.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar